|Last Price||Today's Change||52-Week Range||Trading Volume|
|162.78||0.31 (+0.19%)||130.09 - 181.81||3.6 million (Above Avg)|
Market data as of 4:00PM 11/24/15. Quotes are delayed by at least 15 min.
European Commission Approves Amgen's BLINCYTO® (blinatumomab) for the Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia
11/24/2015 2:00 AM ET
Amgen Announces Repatha® Preferred Position On CVS Health Commercial Formularies
11/23/2015 8:10 AM ET